Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Tafamidis Free Acid Suspension vs Meglumine Capsules in Healthy Subjects
NCT03662191Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (4 arms), sponsored by Pfizer. Primary endpoints: Area under the plasma concentration-time profile from time 0 extrapolated to infinite time and Maximum Observed Plasma Concentration. Started Sep 2018; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT03662191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662191.